WAYNE, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (TFX) (NYSE:TFX), a leading global provider of medical technologies, announced today that a new peer-reviewed study in the Nature ...
Pooled outcomes in more than 330 UroLift ® System subjects treated in a controlled setting were analyzed and reported by Claus Roehrborn et. al. PUL with the UroLift ® System was durable in most ...
Teleflex announces favorable results for UroLift™ in treating BPH, showing higher patient satisfaction and better early recovery compared to Rezūm. Teleflex Incorporated announced new results from the ...
Rates of surgical retreatment, alongside patient experience factors such as complications and adverse events (AEs), are important considerations when patients and their providers assess BPH therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results